For hospital pharmacy committees, clinic procurement teams and pharmacies, seasonal influenza vaccines are a time-bound purchase: strain compositions are reviewed by WHO each year, batches are cold-chain sensitive, and stock planning has to be done before the season starts. This article reports what the manufacturer labels, WHO advisories and Indian bodies publish on quadrivalent influenza vaccines, written for institutional buyers and clinicians. It is informational reporting, not clinical guidance.
Why Influenza Vaccine Procurement Is Seasonal
WHO reports that it convenes twice a year to review global surveillance data and recommend strain compositions, once for the northern hemisphere and once for the southern hemisphere. Manufacturers then update the vaccine formulation to match. According to the prescribing information of quadrivalent products, the strain content changes from season to season, so a previous year’s stock is not a substitute for the current season’s composition. For institutional buyers this means ordering windows, batch expiry and composition labelling all need to be checked each cycle.
What Quadrivalent Labels Report
A quadrivalent inactivated influenza vaccine, as described in its approved prescribing information, contains antigens from two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The product page for Influvac Tetra (quadrivalent influenza vaccine) lists a subunit vaccine containing purified haemagglutinin and neuraminidase surface antigens in a 0.5 mL presentation, with an age indication from 6 months upward as stated on the label. Indication, schedule and administration are defined by the label and by the treating physician; this article does not interpret them for individual patients.
The B/Yamagata Question Hospitals Are Asking
WHO’s influenza vaccine composition advisory groups have reported that confirmed B/Yamagata detections have been absent from global surveillance since the early COVID-19 period, and have advised that the B/Yamagata component be removed from influenza vaccines. Several regulators have since moved toward trivalent compositions, while quadrivalent products remain in supply in other markets. For procurement teams, the practical point reported in regulatory updates is that composition differs by product and by season, so the label and packaging of each batch is the authoritative reference.
Influenza Seasonality in India
Indian surveillance reports describe influenza activity that varies by region, with a monsoon-season rise across much of the country and a winter rise in northern states. Because the timing differs by geography, institutional vaccination committees generally set their own campaign windows. Antibody response after vaccination is reported in prescribing information to develop over a couple of weeks, which is one reason programmes plan stock ahead of the expected activity period.
Groups Listed in Guidelines
WHO position papers and Indian bodies such as the Indian Academy of Pediatrics and ICMR describe groups at higher risk of severe influenza, including young children, older adults, pregnant women, healthcare workers and people with chronic conditions. These lists are used by hospitals when sizing staff and patient programmes. Who is vaccinated, and when, is a decision for the treating physician and the institution’s immunisation policy.
Cold-Chain and Handling Points for Buyers
The prescribing information of the product reviewed here reports storage at 2°C to 8°C in the original packaging, protected from light, with a clear instruction that it must not be frozen. For buyers, that makes the following supply-side points relevant:
- Temperature-controlled packing and transit with monitoring documentation for each consignment.
- Batch number, manufacturing and expiry details matched to the invoice at receipt.
- Sourcing through authorised manufacturer channels, with a licensed distributor holding the required drug licences.
- Seasonal quantity planning agreed in advance, so supply is in place before the institutional campaign date.
Bulk Supply Enquiries for Hospitals, Clinics and Pharmacies
A.K. Pharma is a Delhi-based licensed distributor supplying specialty medicines and vaccines to hospitals, clinics, doctors and pharmacies across India. Institutions planning seasonal influenza programmes can send a bulk or wholesale enquiry for Influvac Tetra through the product page or on 011 4172 6999 / WhatsApp +91 9810034827. Related supply lines such as the infant RSV antibody Beyfortus are listed separately, and our earlier article on epinephrine auto-injectors and anaphylaxis guidance covers an emergency-readiness item that vaccination clinics often review. We handle institutional enquiries only.
Frequently Asked Questions
What does the approved label report about the vaccine type?
According to the manufacturer’s prescribing information, the product reviewed here is a quadrivalent inactivated subunit influenza vaccine containing purified surface antigens (haemagglutinin and neuraminidase) from four virus strains, supplied as a 0.5 mL presentation. Prescribing information is the reference for indication and administration.
Why do vaccine strain compositions change each season?
WHO reports that it reviews global influenza surveillance data and issues strain composition recommendations separately for the northern and southern hemispheres. Manufacturers update vaccine composition accordingly, which is why procurement is planned seasonally rather than carried over.
What did WHO advise about the B/Yamagata component?
WHO’s vaccine composition advisory groups have reported that B/Yamagata viruses have not been confirmed in circulation since early in the COVID-19 period and have advised that the B/Yamagata antigen be removed from influenza vaccines. Regulators and manufacturers are moving at different speeds, so hospitals should confirm the exact composition printed on each batch’s label and packaging.
When does influenza activity peak in India according to surveillance reports?
Published Indian surveillance reports, including those from national public-health bodies, describe influenza activity that varies by region and commonly shows a monsoon-season peak and a winter peak in the north. Seasonal stock planning is therefore usually aligned to regional patterns by the institution’s own vaccination committee.
Which groups do guidelines list as priority for influenza vaccination?
WHO position papers and Indian bodies such as the Indian Academy of Pediatrics and ICMR describe higher-risk groups that include young children, older adults, pregnant women, healthcare workers and people with chronic conditions. Eligibility and scheduling decisions rest with the treating physician or institutional vaccination programme.
What storage conditions does the label report?
The prescribing information reports storage at 2°C to 8°C in the original packaging, protected from light, and states that the vaccine must not be frozen. Cold-chain documentation is therefore a core part of vaccine procurement.
What should procurement teams check on receipt of a vaccine consignment?
Typical checks reported in vaccine handling guidance include batch number and expiry against the invoice, temperature-monitor readings during transit, intact packaging and labelling. Institutions apply their own receiving SOPs.
Does A.K. Pharma give vaccination advice?
No. A.K. Pharma is a distributor, not a healthcare provider. This article is not medical advice, and all vaccination decisions rest solely with the treating physician and the institution’s immunisation programme.
How can hospitals, clinics and pharmacies enquire about bulk supply?
Hospitals, clinics, doctors and pharmacies can send a bulk or wholesale supply enquiry to A.K. Pharma on 011 4172 6999 or WhatsApp +91 9810034827. Retail or individual patient enquiries are not handled.
Disclaimer: A.K. Pharma is a medicine distributor and not a healthcare provider. This article reports information from manufacturer labels, WHO advisories and published guidelines for institutional buyers and clinicians. It is not medical advice and does not recommend any product, dose or treatment. Vaccination and treatment decisions rest solely with the treating physician and the institution’s immunisation programme. Bulk and wholesale enquiries only.
